President Donald Trump announced a sweeping new plan. To reduce prices for weight loss drugs, marking a significant move aimed at expanding affordable healthcare access across the United States. The initiative, known as TrumpRx, focuses on improving affordability for patients seeking treatment with the nation’s most popular weight loss drugs.
Therefore, trump revealed agreements with pharmaceutical giants Novo Nordisk and Eli Lilly, both pledging to slash costs and widen access. Novo Nordisk confirmed that the lowest doses of Wegovy will now cost $149 per month. Therefore, this is significantly easing financial pressure for new users entering treatment programs. This new pricing extends to its self-pay and direct-to-patient options, creating a broader network of affordability.
In addition, Novo Nordisk stated that reductions will apply to key injectable medicines, including Wegovy and Ozempic. The company is also reviewing U.S. self-pay pricing and expects to unveil fresh updates soon. Trump described the move as a victory for public health and a direct benefit to millions seeking better wellness opportunities.
Moreover, That’s roughly $50 below current market rates, matching competitive prices in Europe. Furthermore, Lilly’s oral obesity treatment Orforglipron will launch at $149 per month once approved by regulators, ensuring patients have multiple affordable paths to treatment.
Moreover, under TrumpRx, Medicare participants will pay no more than $50 monthly for Zepbound and Orforglipron. Eli Lilly also revealed discounts of up to 60% for medications like Emgality, Trulicity, and Mounjaro. Such offers represent a major turning point for Americans struggling with escalating prescription costs.
Furthermore, the weight loss drugs program reflects a broader trend toward government-backed affordability partnerships. Both companies have worked closely with Trump’s administration to align with cost-reduction policies designed to match international pricing standards.
Novo Nordisk and Eli Lilly also continue to expand direct-to-consumer platforms like NovoCarePharmacy and LillyDirect. These services enable patients without sufficient insurance coverage to obtain weight loss drugs directly, cutting through red tape and improving nationwide access.
